Evidence map›Paper›PMID 28692537›Full record

ArticleAIDS (London, England)2017

Early initiation of antiretroviral treatment postSIV infection does not resolve lymphoid tissue activation.

Jung J Hong, Eduardo L di Volpe Silveira, Praveen K Amancha, Siddappa N Byrareddy, Sanjeev Gumber, Kyu-Tae Chang, Aftab A Ansari, Francois Villinger

Abstract read
In one paragraph

Article in AIDS (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Role of NKG2a/ciScience · 2021
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Nanotechnology approaches to eradicating HIV reservoirs.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019
    Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Jung J HongaNational Primate Research Center (NPRC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea bDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil cNew Iberia Research Center, University of Louisiana at Lafayette, Lafayette, Louisiana dDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska eDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine fDivision of Pathology, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Eduardo L di Volpe Silveira
Praveen K Amancha
Siddappa N Byrareddy
Sanjeev Gumber
Kyu-Tae Chang
Aftab A Ansari
Francois Villinger
Emory University · USKorea Research Institute of Bioscience and Biotechnology · KRGTx (United States) · USUniversidade de São Paulo · BRUniversity of Louisiana at Lafayette · USUniversity of Nebraska Medical Center · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Gut Homing Cells in SIV infectionR01AI098628 · NIAID · EMORY UNIVERSITY · PI ANSARI, AFTAB A. · 2012 to 2016
$7.0M
Resource for Nonhuman Primate Immune ReagentsR24OD010947 · OD · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VILLINGER, FRANCOIS J · 2012 to 2025
$4.9M
Nebraska Center for VirologyP30GM103509 · NIGMS · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2012 to 2014
$3.3M
PD-1 modulation of SIV specific CD4 and CD8 T cell responsesR01AI078775 · NIAID · EMORY UNIVERSITY · PI VILLINGER, FRANCOIS J · 2009 to 2012
$2.3M
NIAID NIH HHS R01 AI078775NIAID NIH HHS R01 AI098628NIGMS NIH HHS P30 GM103509NIH HHS P51 OD011132NIH HHS R24 OD010947
6 · The paper itself

Abstract

objectiveGerminal center resident follicular helper T (TFH) cells in lymphoid follicles are a potential sanctuary for HIV/simian immunodeficiency virus (SIV) replication. But the dynamics of germinal centers upon early initiation of antiretroviral therapy (ART) and their potential role in the formation of viral sanctuaries post-SIV infection are not fully understood.

designSequential lymph node biopsies (n = 10) were collected from SIVmac239-infected rhesus macaques before infection, at 5 weeks postinfection/pre-ART, 6 and 12 weeks following ART initiation. These tissues and cells were analyzed for frequencies of TFH cells and assignment of germinal center scores.

resultsModest but significant increases in TFH cells and hyperplastic follicles with large germinal centers were noted during the acute phase of SIV infection (week 5/pre-ART). However, 6 weeks after ART initiation, substantial increases in germinal center TFH cells, germinal center B cells, hyperplastic follicles with large germinal centers, and abundant local IL-21 production were observed, whereas levels of SIV RNA and DNA of lymph nodes had decreased to barely detectable values along with barely detectable levels of SIV antibody-producing cells. An additional 6 weeks of ART did not appreciably decrease germinal center TFH or germinal center scores.

conclusionThus, although early ART rapidly controls SIV replication, it does not regulate early lymphoid activation, which may contribute to the seeding and magnitude of viral reservoirs.

Indexed as

Lymphocyte ActivationSecondary PreventionAnimalsAnti-Retroviral AgentsBiopsyLymph NodesMacaca mulattaSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusSustained Virologic ResponseAnti-Retroviral Agents

Identifiers

PMID28692537
PMCPMC5557084
OpenAlexW2731307602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.